A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment

Journal of Substance Abuse Treatment

Volumn 41, Issue 4, 2011, Pages 374-385

  Rieckmann, Traci R ^a   Kovas, Anne E ^b   McFarland, Bentson H ^a,b   Abraham, Amanda J ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Buprenorphine; Multilevel models; Opiate dependence; Substance abuse counselors

Indexed keywords

BUPRENORPHINE; METHADONE;

ACCREDITATION; ADULT; ARTICLE; DETOXIFICATION; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; LEGAL ASPECT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; OPIATE ADDICTION; PATIENT COUNSELING; PHYSICIAN ATTITUDE; PREVALENCE; PRIORITY JOURNAL; SUBSTANCE ABUSE; TRAINING;

ANALGESICS, OPIOID; ATTITUDE; ATTITUDE OF HEALTH PERSONNEL; BUPRENORPHINE; COUNSELING; CULTURE; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS;

EID: 82455210923     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.05.005     Document Type: Article

References (83)

1. Aarons G.A. Mental health provider attitudes toward adoption of evidence-based practice: The Evidence-Based Practice Attitude Scale (EBPAS). Mental Health Services Research 2004, 6:61-74.
2. Abraham A.J., Ducharme L.J., Roman P.M. Counselor attitudes toward pharmacotherapies for alcohol dependence. Journal of Studies on Alcohol and Drugs 2009, 70:628-635.
3. Alexander J.A., Wheeler J.R., Nahra T.A., Lemak C.H. Managed care and technical efficiency in outpatient substance abuse treatment units. The Journal of Behavioral Health Services & Research 1998, 25:377-396.
4. Amass L., Ling W., Freese T., Reiber C., Annon J., Cohen A., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. The American Journal of Addictions 2004, 13:542-566.
5. Amato L., Davoli M., Ferri M., Gowing L., Perucci C.A. Effectiveness of interventions on opiate withdrawal treatment: An overview of systematic reviews. Drug and Alcohol Dependence 2004, 73:219-226.
6. Anton R., Moak D., Waid R., Latham P., Malcolm R., Dias J. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. The American Journal of Psychiatry 1999, 156:1758-1764.
7. Barnett P., Rodgers J., Bloch D. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001, 96:683-690.
8. Bartholomew N.G., Joe G.W., Rowan-Szal G.A., Simpson D.D. Counselor assessments of training and adoption barriers. Journal of Substance Abuse Treatment 2007, 33:193-199.
9. Bell J.R., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug and Alcohol Dependence 2009, 104:73-77.
10. Boyd C.J., Teter C.J., West B.T., Morales M., McCabe S.E. Non-medical use of prescription analgesics: A three-year national longitudinal study. Journal of Addictive Diseases 2009, 28:232-242.
11. Bryk A., Raudenbush S. Hierarchical linear models: Applications and data analysis methods 2002, Sage Publications, Thousand Oaks, CA. 2nd ed.
12. Center for Substance Abuse Treatment Medication-assisted treatment for opioid addiction in opioid treatment programs 2005, Substance Abuse and Mental Health Administration, Rockville, MD.
13. Center for Substance Abuse Treatment Buprenorphine: A guide for nurses 2009, Substance Abuse and Mental Health Administration, Rockville, MD.
14. Chassin M.R., Loeb J.M., Schmaltz S.P., Wachter R.M. Accountability measures-Using measurement to promote quality improvement. The New England Journal of Medicine 2010, 363:683-688.
15. Chriqui J.F., Terry-McElrath Y., McBride D.C., Eidson S.S., VanderWaal C.J. Does state certification or licensure influence outpatient substance abuse treatment program practices?. Journal of Behavioral Health Services and Research 2007, 34:309-328.
16. Compton W., Volkow N. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence 2006, 81:103-107.
17. Cook J.M., Biyanova T., Coyne J.C. Barriers to adoption of new treatments: An Internet study of practicing community psychotherapists. Administration and Policy in Mental Health 2009, 36:83-90.
18. Denisco R., Chandler R., Compton W. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Experimental and Clinical Psychopharmacology 2008, 16:417-428.
19. Ducharme L., Knudsen H., Roman P. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment 2007, 32:321-329.
20. Ducharme L., Roman P. Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption. Journal of Substance Abuse Treatment 2009, 37:90-94.
21. Egan J.E., Casadonte P., Gartenmann T., Martin J., McCance-Katz E.F., Netherland J., et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): A novel project to expand/improve buprenorphine treatment. Journal of General Internal Medicine 2010, 25:936-941.
22. Fiellin D.A., Pantalon M.V., Pakes J.P., O'Connor P.G., Chawarski M., Schottenfeld R.S. Treatment of heroin dependence with buprenorphine in primary care. American Journal of Drug and Alcohol Abuse 2002, 28:231-241.
23. Fixsen D.L., Naoom S.F., Blase K.A., Friedman R.M., Wallace F. Implementation research: A synthesis of the literature 2005, University of South Florida, Louis de la Parte Florida Mental Health Institute, Tampa, FL.
24. Friedmann P.D., Jiang L., Alexander J.A. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. The Journal of Behavioral Health Services & Research 2010, 37:322-337.
25. Fuller B., Rieckmann T., McCarty D., Smith K., Levine H. Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment 2005, 28:273-280.
26. Garner B.R. Research on the diffusion of evidence-based treatments within substance abuse treatment: A systematic review. Journal of Substance Abuse Treatment 2009, 36:376-399.
27. Glisson C., Landsverk J., Schoenwald S., Kelleher K., Hoagwood K.E., Mayberg S., Research Network on Youth Mental Health Assessing the organizational social context (OSC) of mental health services: Implications for research and practice. Administration and Policy in Mental Health 2008, 35:98-113.
28. Hall A.J., Logan J.E., Toblin R.L., Kaplan J.A., Kraner J.C., Bixler D., et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. Journal of American Medical Association 2008, 300:2613-2620.
29. Horgan C.M., Reif S., Ritter G.A., Lee M.T. Organizational and financial issues in the delivery of substance abuse treatment services. Recent Developments in Alcoholism 2001, 15:9-26.
30. Johnson R., Chutuape M., Strain E., Walsh S., Stitzer M., Bigelow G. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. The New England Journal of Medicine 2000, 343:1290-1297.
31. Johnson R., Eissenberg T., Stitzer M., Strain E., Liebson I., Bigelow G. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence 1995, 40:17-25.
32. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future national survey results on drug use, 1975-2006: Volume I, secondary school students. NIH publication no. 07-6205 2007, National Institute on Drug Abuse, Bethesda, MD.
33. Joint Commission. (2010). Facts about behavioral health care accreditation. Oakbrook Terrace, IL: Joint Commission. http://www.jointcommission.org/assets/1/18/Behavioral_Health_Care_Accreditation.pdf.
34. Kakko J., Svanborg K., Kree M., Hellig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomized, placebo-controlled trial. The Lancet 2003, 361:662-668.
35. Kasarabada N.D., Hser Y.I., Parker L., Hall E., Anglin M.D., Chang E. A self-administered instrument for assessing therapeutic approaches of drug-user treatment counselors. Substance Use and Misuse 2001, 36:273-299.
36. Kitson A.L. The need for systems change: Reflections on knowledge translation and organizational change. Journal of Advanced Nursing 2009, 65:217-228.
37. Knudsen H., Abraham A., Johnson A., Roman P. Buprenorphine adoption in the National Drug Abuse Clinical Trials Network. Journal of Substance Abuse Treatment 2009, 37:307-312.
38. Knudsen H., Ducharme L., Roman P. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence 2006, 87:164-174.
39. Knudsen H., Ducharme L., Roman P. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment 2006, 30:363-373.
40. Knudsen H., Ducharme L., Roman P. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence 2007, 87:164-174.
41. Knudsen H., Ducharme L., Roman P., Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment 2005, 29:95-106.
42. Knudsen H.K., Ducharme L.J., Roman P.M. Research network involvement and addiction treatment center staff: Counselor attitudes toward buprenorphine. The American Journal on Addictions 2007, 16:365-371.
43. Koch A.L., Arfken C.L., Schuster C.R. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug and Alcohol Dependence 2006, 83:274-278.
44. Ling W., Charuvastra C., Collins J., Batki S., Brown L., Kintaudi P., et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998, 93:475-486.
45. Ling W., Huber A., Rawson R. New trends in opiate pharmacotherapy. Drug and Alcohol Review 2001, 20:79-94.
46. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005, 100:1090-1100. Buprenorphine Study Protocol Group.
47. Lundgren L., Krull I., Zerden L.D., McCarty D. Community based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions. Evaluation and Program Planning 2001, 34:356-365.
48. Mark T., Kassed C., Vandivort-Warren R., Levit K., Kranzler H. Alcohol and opioid dependence medications: Prescription trends overall and by physician activity. Drug and Alcohol Dependence 2009, 99:345-349.
49. Mark T., Kranzler H., Poole V., Hagen C., McLeod C., Crosse S. Barriers to the use of medications to treat alcoholism. The American Journal of Addiction 2003, 12:281-294.
50. Mark T.L., Woody G.E., Juday T., Kleber H.D. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence 2001, 61:195-206.
51. McCarty D., Rieckmann T., Green C., Gallon S., Knudsen H. Training rural practitioners to use buprenorphine: Using the change book to facilitate technology transfer. Journal of Substance Abuse Treatment 2004, 26:203-208.
52. McDowell D.M., Cocke C. Office-based treatment of opiate-dependent patients with buprenorphine: It's about time. Primary Psychiatry 2006, 13:68-73.
53. McGovern M., Fox T., Xie H., Drake R. A survey of clinical practices and readiness to adopt evidence-based practices: Dissemination research in an addiction treatment system. Journal of Substance Abuse Treatment 2004, 26:305-312.
54. McKenzie M., Nunn A., Zaller N.D., Bazazi A.R., Rich J.D. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: Implications for policy and practice. Journal of Opioid Management 2009, 5:219-227.
55. Monti P., Rohsenow D., Swift R., Gulliver S., Colby S., Mueller T., et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcoholism: Clinical and Experimental Research 2001, 25:1634-1647.
56. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective medical treatment of opiate addiction. Journal of American Medical Association 1998, 280:1936-1943.
57. Netherland J., Botsko M., Egan J.E., Saxon A.J., Cunningham C.O., Finkelstein R. Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment 2009, 36:244-251. BHIVES Collaborative.
58. Novak S., Ball J. Emergency department visits involving nonmedical use of selected pharmaceuticals. No. 23) 2006, Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD.
59. Oser C.B., Roman P.M. Organizational-level predictors of adoption across time: Naltrexone in private substance-use disorders treatment centers. Journal of Studies on Alcohol and Drugs 2007, 68:852-861.
60. Pagoto S.L., Spring B., Coups E.J., Mulvaney S., Coutu M.F., Ozakinci G. Barriers and facilitators of evidence-based practice perceived by behavioral science health professionals. Journal of Clinical Psychology 2007, 63:695-705.
61. Raudenbush S.W., Bryk A.S., Congdon R.T. HLM 6.08 (computer software) 2004, Scientific Software International, Lincolnwood, IL.
62. Ridge G., Gossop M., Lintzeris N., Witton J., Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment 2009, 37:95-100.
63. Rieckmann T., Daley M., Fuller B., Thomas C., McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. Journal of Substance Abuse Treatment 2007, 32:207-215.
64. Diffusion of innovations 2003, 423-424. Free Press, New York. 5th ed. E.M. Rogers (Ed.).
65. Schroeder S.A. An agenda to combat substance abuse. Health Affairs 2005, 24:1005-1013.
66. Schwartz R., Kelly S., O'Grady K., Mitchell S., Peterson J., Reisinger H., et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. American Journal on Addictions 2008, 17:396-401.
67. Simpson D.D., Flynn P.M. Moving innovations into treatment: A stage-based approach to program change. Journal of Substance Abuse Treatment 2007, 33:111-120.
68. Snijders T.A.B., Bosker R.J. Multilevel analysis: An introduction to basic and advanced multilevel modeling 1999, Sage, London, United Kingdom.
69. Stein M., Cioe P., Friedmann P. Buprenorphine retention in primary care. Journal of General Internal Medicine 2005, 20:1038-1041.
70. Substance Abuse and Mental Health Services Administration National Household Survey on Drug Abuse: Main findings 1998 2000, U.S. Department of Health and Human Services, Rockville, MD.
71. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National findings (office of applied studies, NSDUH series H-36, HHS publication no. SMA 09-4434) 2009, U.S. Department of Health and Human Services, Rockville, MD.
72. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Heroin and other opiate admissions to substance abuse treatment: The TEDS report 2009, U.S. Department of Health and Human Services, Rockville, MD.
73. Sullivan L., Chawarski M., O'Connor P., Schottenfeld R., Fiellin D. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment?. Drug and Alcohol Dependence 2005, 79:113-116.
74. Thomas C., Reif S., Haq S., Wallack S., Hoyt A., Ritter G. Use of buprenorphine for addiction treatment perspectives of addiction specialists and general psychiatrists. Psychiatric Services 2008, 59:909-916.
75. Thomas C., Wallack S., Lee S., McCarty D., Swift R. Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment 2003, 24:1-11.
76. Thomas S.E., Miller P.M. Knowledge and attitudes about pharmacotherapy for alcoholism: A survey of counselors and administrators in community-based addiction treatment centres. Alcohol and Alcoholism 2007, 42:113-118.
77. Thomas C.P., Garnick D.W., Horgan C.M., McCorry F., Gmyrek A., Chalk M., et al. Advancing performance measures for use of medications in substance abuse treatment. Journal of Substance Abuse Treatment 2011, 40:35-43.
78. Vergara-Rodriguez P., Tozzi M.J., Botsko M., Nandi V., Altice F., Egan J.E., et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. Journal of Acquired Immune Deficiency Syndromes 2011, 56(Suppl 1):S62-S67. BHIVES Collaborative.
79. Wallack S.S., Thomas C.P., Martin T.C., Chilingerian J., Reif S. Substance abuse treatment organizations as mediators of social policy: Slowing the adoption of a congressionally approved medication. Journal of Behavioral Health Services & Research 2010, 37:64-78.
80. Walley A., Alperen J., Cheng D., Bottice M., Castro-Donlan C., Samet J., et al. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine 2008, 23:1393-1398.
81. Weiss L., Netherland J., Egan J.E., Flanigan T.P., Fiellin D.A., Finkelstein R., et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: Lessons from the BHIVES collaborative. Journal of Acquired Immune Deficiency Syndromes 2011, 56(Suppl 1):S68-S75. BHIVES Collaborative.
82. White W., Kurtz E. The varieties of recovery experience 2005, Great Lakes Addiction Technology Transfer Center, Chicago, IL.
83. Ziedonis D.M., Amass L., Steinberg M., Woody G., Krejci J., Annon J.J., et al. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA Clinical Trials Network drug and alcohol dependence. Drug and Alcohol Dependence 2009, 99:28-36.